In an exclusive interaction with Thiruamuthan, Assistant Editor at India Pharma Outlook, Dhananjay Singh, Managing Director, Merck Life Science, discusses India's evolving life sciences landscape, the challenges of commercializing research, and the i
Lilly’s triple agonist retatrutide outmuscles Ozempic on weight loss, delivering greater weight reduction and blood sugar control in trials.
GSK and Hansoh's Ris-Rez shows promise in osteosarcoma treatment, reducing progression risk in a Phase III trial and highlighting unmet needs after relapse.
Roche’s next-generation drug divarasib cuts lung cancer death risk by 44%, offering longer survival and improved treatment tolerability.
CLDN18.2 testing is gaining attention as AstraZeneca's experimental stomach cancer drug shows survival benefits, potentially widening eligibility for targeted treatment among patients.
Novartis' Remibrutinib data highlight new findings on relapse reduction, disability progression and the potential role of oral therapies in multiple sclerosis.
The AbbVie lutikizumab trial met its Phase 3 primary endpoint in hidradenitis suppurativa, while the company prepares to explore an obesity-focused combination strategy.
Vor Bio kidney drug telitacicept shows promise in preserving kidney function over two years in a Phase 3 IgA nephropathy trial.
Moderna stock slumps on cancer shot data, while Pfizer and Valneva advance Lyme vaccine prospects and malaria vaccine prices fall.
Eosinophilic esophagitis treatment gains a potential new option as AstraZeneca and Amgen report sustained remission and symptom improvements with Tezspire.